(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted it a new patent protecting Tedopi®, its therapeutic cancer vaccine, for the treatment of certain cancer patients non-small cell lung.
This new patent reinforces the value of Tedopi® and ensures the protection of the product in the United States until 2037.
This additional protection of Tedopi®, OSE Immunotherapeutics’ most advanced clinical asset, reinforces the value of the Company’s product portfolio.